Business Description
Innate Pharma SA
ISIN : FR0010331421
Share Class Description:
IPHYF: Class ATotal Employee Number:
163Compare
Compare
Traded in other countries / regions
IPH.FranceIPHA.USA0EVI.UKIDD.Germany IPO Date
2013-04-23Description
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.52 | |||||
Equity-to-Asset | -0.35 | |||||
Debt-to-Equity | -1.04 | |||||
Debt-to-EBITDA | -0.52 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -11 | |||||
Beneish M-Score | 12.92 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -63.2 | |||||
3-Year EBITDA Growth Rate | -46.8 | |||||
3-Year EPS without NRI Growth Rate | -42.1 | |||||
3-Year FCF Growth Rate | -15.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 33.91 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 95.37 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 17.35 | |||||
9-Day RSI | 32.9 | |||||
14-Day RSI | 40.56 | |||||
3-1 Month Momentum % | 63.93 | |||||
6-1 Month Momentum % | 4.41 | |||||
12-1 Month Momentum % | 15.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.27 | |||||
Quick Ratio | 1.27 | |||||
Cash Ratio | 0.94 | |||||
Days Sales Outstanding | 61.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.6 | |||||
Shareholder Yield % | 5.71 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1916.94 | |||||
Net Margin % | -1764.51 | |||||
EBITDA Margin % | -1566.06 | |||||
FCF Margin % | -1247.06 | |||||
OCF Margin % | -1161.97 | |||||
ROA % | -55.31 | |||||
ROIC % | -127.96 | |||||
3-Year ROIIC % | 87.52 | |||||
ROC (Joel Greenblatt) % | -1012.26 | |||||
ROCE % | -87.21 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 12.41 | |||||
PS Ratio | 50.84 | |||||
EV-to-EBIT | -2.8 | |||||
EV-to-EBITDA | -3.12 | |||||
EV-to-Revenue | 48.89 | |||||
EV-to-Forward-Revenue | 22.76 | |||||
EV-to-FCF | -3.9 | |||||
Price-to-GF-Value | 11 | |||||
Price-to-Median-PS-Value | 7.86 | |||||
Earnings Yield (Greenblatt) % | -35.71 | |||||
FCF Yield % | -23.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:IPHYF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Innate Pharma SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.234 | ||
| EPS (TTM) ($) | -0.639 | ||
| Beta | 0.0641 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.34 | ||
| Volatility % | 86.98 | ||
| 14-Day RSI | 40.56 | ||
| 14-Day ATR ($) | 0.015914 | ||
| 20-Day SMA ($) | 1.65 | ||
| 12-1 Month Momentum % | 15.38 | ||
| 52-Week Range ($) | 1.31 - 2.25 | ||
| Shares Outstanding (Mil) | 93.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Innate Pharma SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Innate Pharma SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 130 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 130 days | ||
| Second quarter earnings conference call for 2026 | 2026-09-17 | In 81 days | ||
| Second quarter earnings results for 2026 | 2026-09-17 | In 81 days | ||
| Guidance call for 2026 | 2026-06-02 | 1.65 (+0.00%) | ||
| General meeting for 2026 | 2026-05-21 10:30 | 2.25 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 07:30 | 1.50 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 1.50 (+0.00%) | ||
| Annual report for 2025 | 2026-04-01 | 1.37 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 09:00 | 1.37 (+0.00%) |
Show
Entries
Innate Pharma SA Frequently Asked Questions
What is Innate Pharma SA(IPHYF)'s stock price today?
The current price of IPHYF is $1.65. The 52 week high of IPHYF is $2.25 and 52 week low is $1.31.
When is next earnings date of Innate Pharma SA(IPHYF)?
The next earnings date of Innate Pharma SA(IPHYF) is 2026-09-17.
Does Innate Pharma SA(IPHYF) pay dividends? If so, how much?
Innate Pharma SA(IPHYF) does not pay dividend.
Guru Commentaries on OTCPK:IPHYF
No articles.
Press Release
Articles on Innate Pharma SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers